web analytics
0.1 C
Saturday, December 3, 2022

Gold Standard Cell-In-The-Box Technology: Pharmacyte Biotech Inc (OTCMKTS:PMCB)

Pharmacyte Biotech Inc (OTCMKTS:PMCB) continues to rise off its $0.05 established support levels in recent weeks since the pop its made over $0.15 at the end of last year. The stock is now nearing $0.05 support levels for a second test. PMCB has a long history of big moves trading as high as $0.60 in 2014 and is an Investors favorite with a large and faithful shareholder base.

PMCB has been around for years as Nuvilex but changed its name on January 8 of this year. The ticker symbol changed from NVLX to PMCB. The stock is an Investors favorite with a huge online following.

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon their unique, proprietary and patented cellulose-based live cell encapsulation technology known as Cell-in-a-Box®.

PMCB has been around for years and was initially incorporated as eFoodSafety.com, Inc. in 1996 in Nevada. The recent move up comes after PMCB outlined 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.

The live-cell encapsulation technology employed by Pharmacyte Biotech is a way to enclose living cells in protective “cocoons” about the size of the head of a pin. Each capsule can enclose approximately 10,000 cells and the technology is considered a “platform” upon which treatments can be developed.

Dr.Mark Rabe, chairman of the advisory board of Pharmacyte Biotech subsidiary, Medical Marijuana Sciences (MMS) summed it up perfectly when he said ”The live cell encapsulation platform employed by Nuvilex is a unique patented technology on which treatments can be developed for deadly and debilitating diseases such as cancer and diabetes. The technology has shown to be successful in the treatment of pancreatic cancer in initial clinical trials using the conventional chemotherapy drug ifosphamide. ”

To get a sense of just how valuable this technology could be, consider a recent report published by U.S. based market research company, Transparency Market Research “ the global diabetes devices and drugs market was valued at USD 54.04 billion in 2012 and is estimated to reach a market worth of USD 83.0 billion in 2019 growing at a CAGR of 5.9% from 2013 to 2019.

Many investors in the Company view Pharmacyte Biotech Cell-in-a-Box® cell encapsulation technology as THE future of diabetes treatment and suggest the Company is a prime buy out candidate from a major such as Bayer who may be closely watching PMCB.

To Find out the inside Scoop on PMCB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

PMCB stared trading on the OTCBB on January 8 after the name change from Nuvilex, Inc. The ticker symbol changed from NVLX to PMCB. The Company said that the name change is part of its transformation process to operate solely as a pure biotechnology firm leveraging its Cell-in-a-Box®

The stock has benefited from the pot connection; the sector is heating up again big time with a recent report from MMJ Business Daily suggesting that 2015 is expected not only to see more investment dollars flow into the market but it could even outpace the growth rate seen in 2014. States like Nevada, Illinois, Massachusetts, Oregon, and Alaska have all been identified as industry drivers this year. Furthermore, the rise in “big money” from some major investment funds has just started to hit the sector.

PMCB landed a leading figure in the medical marijuana field in Dr. Mark L. Rabe who was appointed as the Chairman of the Scientific Advisory Board of Medical Marijuana Sciences (MMS).

In fact Pharmacyte Biotech has been very successful in attracting top talent to the Company including their COO Dr. Crabtree who used to work at Bristol Meyers and successfully managed the project that achieved FDA approval for Taxol.

On September 7 PMCB announced it has reached an agreement with Austrianova to restructure certain agreements between them pursuant to a Binding Term Sheet (Term Sheet). The Term Sheet provides that PharmaCyte’s obligation to make milestone payments under the Asset Purchase Agreement, the Diabetes Licensing Agreement and the Cannabis Licensing Agreement are eliminated in their entirety. Also, the royalty fees and sublicensing royalty fees are reduced in the two licensing agreements. The Term Sheet further amends the Diabetes Licensing Agreement by expanding the scope of the licensed rights to cover encapsulation of all cell types and cells lines of any kind now in existence or later identified, including stem cells at all stages of differentiation and from any source specifically designed to produce insulin for the treatment of diabetes.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $58 million market valuation PMCB has $4.2 million in the treasury, no revenues to date and fast rising short term debt. But PMCB is an exciting story developing in small caps; not only does PMCB have a history of explosive moves the stock has a loyal shareholder base who believes this one moves much higher. The Company has made some huge steps recently towards accelerated FDA approval for its pancreatic cancer treatment using Phase 2b data that outperformed Eli Lilly’s Gemzar in prior trials; according to available information the Cell-In-The-Box technology beats the current Gold Standard on The market, and we are talking about a market worth billions. We will be updating on PMCB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PMCB.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in PMCB either long or short and we have not been compensated for this article.

More articles



Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.